Bruker

What Bruker does

Bruker Corporation (NASDAQ: BRKR), founded in 1960 in Billerica, Massachusetts, is a global developer and manufacturer of high-performance scientific instruments and analytical/diagnostic solutions. The company's product portfolio spans mass spectrometry (timsTOF, timsMRMS, timsOmni — including the proprietary trapped ion mobility platform achieving 10M+ mass resolution), nuclear magnetic resonance (NMR, where Bruker introduced the world's first commercial instrument in 1960 and continues to push to 1.3 GHz systems), X-ray fluorescence (WDXRF, EDXRF), FT-IR and Raman spectroscopy, magnetic resonance imaging (including the 18 Tesla BioSpec preclinical MRI), electron and fluorescence microscopy, spatial biology platforms (GeoMx DSP, CosMx SMI, CellScape XR, PaintScape), and clinical microbiology diagnostics (MALDI Biotyper with FDA Claims 7/8 and 5,300+ validated species library, IR Biotyper, MyGenius PRO PCR system). The company operates from over 90 locations across all continents with approximately 11,000 employees, serving life-sciences research, pharmaceutical/biopharma, clinical diagnostics, semiconductor (via the 2026 TOFWERK acquisition), industrial materials, food and agriculture, and environmental/forensics end markets.

Bruker generates revenue primarily through direct enterprise sales of capital instruments under custom quote-based, multi-year contracts, complemented by a recurring revenue stream from consumables, reagents, software licenses, and LabScape service agreements tied to its installed base (with FY2025 double-digit consumables growth in the U.S. reported). The company also operates the Bruker Store e-commerce channel for consumables and accessories. Distribution is primarily direct sales with regional distributor support and select strategic channel partnerships, including Hitachi High-Tech commercializing MyGenius PRO as LABOSPECT GA-5 in Japan. Customer logos span pharmaceutical companies, academic research institutions (e.g., Champalimaud Foundation with the 18T MRI), semiconductor manufacturers, clinical labs (e.g., European transplant centers for MyGenius PRO), and food quality labs (e.g., Pahadi Story honey authentication via NMR).

Bruker has executed an aggressive multi-year acquisition strategy, completing over a dozen deals since 2022 totaling more than $1.4 billion in disclosed consideration — most notably ELITechGroup ($930.9M in 2024), NanoString Technologies ($392.6M in 2024), PhenomeX ($108M in 2023), and Spectral Instruments Imaging ($37.5M in 2024) — to build an integrated multi-omics and diagnostics franchise from single-cell analysis through spatial biology, proteomics, metabolomics, and clinical molecular diagnostics. The 2024 $403M public equity raise was used to repay acquisition debt. Management has guided FY2026 revenue to $3.57-3.60B against an FY2025 base of approximately $3.4B, though Q1 2026 organic revenue declined 4.4% YoY, indicating underlying instrument demand softness offset by acquired entity contribution.

Name

Bruker

Legal name

Bruker Corporation

Website

https://bruker.com

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Bruker Corporation (NASDAQ: BRKR) is a global manufacturer of high-performance scientific instruments and analytical/diagnostic solutions spanning mass spectrometry, NMR, X-ray, FT-IR, microscopy, spatial biology, preclinical imaging, and clinical microbiology, serving pharmaceutical, academic, clinical diagnostics, semiconductor, industrial, and food-safety markets.

Ownership category

akta.pro rank

Product category

Scientific Instruments and Analytical Solutions

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Metrology, Calibration & Testing Equipment (Balances, pH/DO, Standards) (HLAGAIAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)

Keywords

• Scientific instruments
• Mass spectrometry
• NMR spectroscopy
• X-ray fluorescence
• Molecular diagnostics

Headquarters

HQ city

Billerica

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Scientific Instruments and Analytical Solutions: Bruker generates the majority of its revenue from selling high-performance scientific instruments including mass spectrometers, NMR systems, X-ray spectrometers, FT-IR and Raman instruments, microscopes, and preclinical imaging systems. These are typically sold as capital equipment with associated software and installation services.
2. Diagnostic Systems and Tests: Revenue from microbiology and infection diagnostics products including MALDI Biotyper systems, IR Biotyper, MyGenius PRO molecular diagnostics, and related consumables and reagents for clinical laboratories.
3. Software, Services, and Consumables: Recurring revenue from software licenses, maintenance service agreements (LabScape), training, and consumables including reagents, spare parts, and accessories. Bruker's installed base of instruments generates ongoing consumables and service revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Bruker designs, manufactures, and sells high-performance scientific instruments and analytical/diagnostic solutions used by life sciences researchers, pharmaceutical and biopharma companies, clinical laboratories, semiconductor manufacturers, and industrial quality-control customers. Core offerings include mass spectrometry (timsTOF, timsMRMS), NMR and preclinical MRI systems, X-ray fluorescence and FT-IR spectrometers, electron and fluorescence microscopes, microbiology and molecular diagnostics systems (MALDI Biotyper, IR Biotyper, MyGenius PRO), spatial biology platforms (GeoMx DSP, CosMx SMI, CellScape XR, PaintScape), and nanomechanical test instruments, plus associated software, consumables, and service agreements.

Product overview

Bruker is a developer, manufacturer, and distributor of high-performance scientific instruments and analytical/diagnostic solutions organized into distinct product lines. The portfolio includes: (1) Elemental Analyzers (S8 TIGER XRF, TITAN handheld XRF, MOVE-T dairy analyzers); (2) Infrared/Raman Spectroscopy (VERTEX NEO Ultra FT-IR); (3) Mass Spectrometry (timsTOF, timsMRMS, timsUltra, timsOmni platforms for proteomics, metabolomics, and energy research); (4) Nuclear Magnetic Resonance (AVANCE NMR spectrometers, Fourier 80 Duo benchtop NMR, 1.3 GHz ultra-high field systems); (5) Microbiology & Diagnostics (MALDI Biotyper, IR Biotyper, MyGenius PRO PCR system, ELITechGroup molecular diagnostics); (6) Spatial Biology (GeoMx DSP, CellScape XR, PaintScape, CosMx SMI from NanoString acquisition); (7) Preclinical Imaging (BioSpec MRI systems); (8) Fluorescence Microscopy (Papilio5D light-sheet); (9) Test & Measurement (Hysitron nanoindentation, Dimension IconIR AFM-IR); and (10) Software/Services (LabScape Cloud, OmniScape, Spectronaut, SpectroMine). Bruker's products serve life sciences research, pharmaceutical/biopharma, clinical diagnostics, industrial quality control, food safety, environmental monitoring, and semiconductor manufacturing markets.

Differentiator

Problem solved

Functional benefit

Brands

• MyGenius PRO: High-throughput fully automated sample-to-answer molecular diagnostics system based on PCR technology for infectious disease testing
• MALDI Biotyper
• IR Biotyper
• timsMRMS
• InGenius
• BeGenius
• LiquidArray
• Fourier 80 Duo
• AVANCE NEO-X
• timsTOF
• BioSpec
• LabScape
• ELITechGroup
• Chemspeed

Products and services

• S8 TIGER Series 3 WDXRF Spectrometer Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer with AI-assisted operation, HighSense detectors with SensorBoost, up to 4 kW power, EasyLoad camera AI, TouchControl touchscreen, SafeGuard predictive maintenance, and LabScape Cloud for fleet management. Used for elemental analysis in mining, cement, metals, and petrochemical industries.
• TITAN Handheld XRF Analyzer Handheld XRF analyzer built for industrial use with a dust, water, chemical, and shock-resistant casing for material identification and elemental analysis.
• VERTEX NEO Ultra FT-IR Spectrometer Top-tier bench-top vacuum FT-IR spectrometer offering the highest resolution, broadest spectral range, best signal-to-noise ratio, and full automation for research applications.
• MOVE-T Liquid Dairy Analyzer Compact FT-NIR analyzer for rapid and reliable analysis of milk, liquid dairy, and plant-based alternatives with 2-in-1 sample handling for quality control.
• Papilio5D Light-Sheet Microscope Multi-sample and dual-view light-sheet microscope ideal for organoids and 3D cell cultures for fluorescence microscopy applications.
• Hysitron PI Envision SEM PicoIndenter Compact, upgradable in-situ SEM nanoindentation system with extended capabilities for nanomechanical and nanotribological testing.
• timsMRMS Mass Spectrometry Platform Novel mass spectrometry platform combining Trapped Ion Mobility Spectrometry with extreme-resolution Magnetic Resonance Mass Spectrometry for ultra-high-resolution analysis of energy materials, batteries, and biofuels. Achieves mass resolution exceeding 10 million with sub-parts-per-million mass accuracy and isotope fine structure identification.
• timsUltra AIP Mass Spectrometer Enhanced timsTOF mass spectrometer with breakthrough proteomics capabilities enabling identification and quantification of over 10,000 proteins per sample at 500 samples per day throughput.
• timsOmni Mass Spectrometer Mass spectrometer with 4x sensitivity improvements for top-down proteoform analysis in proteomics research.
• MyGenius PRO Molecular Diagnostics System Fully automated sample-to-answer molecular diagnostics system based on PCR technology for infectious disease testing, developed with Hitachi High-Tech Corporation and ELITechGroup. IVDR-compliant assays for CMV, EBV, BK virus at launch.
• MALDI Biotyper sirius CA System MALDI-TOF mass spectrometer for rapid microbial identification with FDA Claims 7 and 8 capabilities and reference libraries covering 5,300+ species including 549 clinically validated microbial species.
• IR Biotyper Infrared spectroscopy-based microbial strain typing system for outbreak management in clinical microbiology settings.
• MBT Easy T Kit Standardized MALDI-TOF sample preparation kit for consistent and efficient sample transfer for microbial identification.
• CellScape XR Spatial Proteomics Platform High-plex spatial proteomics platform with 208-plex capability linking with GeoMx DSP and CosMx SMI for integrated spatial biology insights and high-resolution spatial analysis of protein expression in tissue samples.
• PaintScape Spatial Biology Platform Spatial biology platform featuring 419-plex ChromoPaint panel for 3D genome visualization, with planned 1000+-plex OncoPaint panel.
• BioSpec 18 Tesla Preclinical MRI System World's highest-field horizontal-bore preclinical MRI system at 18 Tesla for advanced cancer and neuroscience research with increased spatial resolution and sensitivity.
• AVANCE NEO-X NMR Console Advanced NMR console electronics for enhanced NMR spectroscopy performance and workflow automation.
• Fourier 80 Duo Benchtop FT-NMR System 80 MHz benchtop FT-NMR system designed for chemistry, pharmaceutical, and materials science research applications.
• Dimension IconIR Photothermal AFM-IR Spectroscopy System Photothermal AFM-IR spectroscopy system for nanoscale chemical characterization in semiconductor research applications.
• TOFWERK Airborne Molecular Contaminants Solutions Compact, high-precision QCL-based multi-gas analyzers and airborne molecular contaminants solutions for semiconductor, environmental, and industrial monitoring applications.
• GeoMx DSP Digital Spatial Profiler Digital Spatial Profiler for spatial genomics and transcriptomics analysis enabling high-plex protein and RNA expression profiling from tissue sections.
• CosMx SMI Spatial Molecular Imager Single Molecule Imaging platform for spatial transcriptomics providing sub-cellular resolution of RNA expression in tissue samples.

Quantifiable outcome

• 140 new system placements in 2025 with double-digit consumables growth in the U.S.
• +5 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature15 records

Partnerships

17 partnerships are on record, tiered minor and core.

• SISCAPA Assay TechnologiesminorStrategic or Co-development Partner · 12 June 2026Collaboration between Biognosys and SISCAPA Assay Technologies to develop ultra-sensitive targeted protein assays for clinical research, announced at ASMS 2026.
• Biocrates Life Sciences AG (Partnership with Bruker)minorStrategic or Co-development Partner · 12 June 2026Biognosys expanded its hybrid metabolomics offerings through a partnership with Bruker and Biocrates, integrating metabolomics and lipidomics technologies for clinical research applications.
• Hitachi High-Tech CorporationcoreStrategic or Co-development Partner · 17 April 2026Co-development partnership for the MyGenius PRO automated molecular diagnostics system. Hitachi High-Tech co-developed the PCR-based sample-to-answer platform with ELITechGroup (a Bruker company). Hitachi High-Tech separately commercializes the platform as LABOSPECT GA-5 in Japan under Japanese diagnostic regulations, expanding Bruker's molecular diagnostics reach in the Asia-Pacific region.
• ImeccoreStrategic or Co-development Partner · 7 April 2026Joint Development Project for photothermal AFM-IR spectroscopy technology for semiconductor research. Bruker installed its Dimension IconIR system at imec in Belgium to evaluate nanoscale chemical characterization for next-generation semiconductor devices including EUV photoresist patterning, advanced materials for transistor scaling, and site-selective surface functionalization.
• TOFWERKcoreTechnology or Integration · 1 January 2026Bruker entered the semiconductor manufacturing market with TOFWERK airborne molecular contaminants solutions following its January 2026 acquisition, securing a multi-million dollar multiple-systems order from a leading global memory manufacturer.
• Biocrates Life Sciences AGcoreTechnology or Integration · 1 June 2025Bruker acquired Austria-based Biocrates Life Sciences AG in June 2025 to strengthen its multiomics capabilities by integrating Biocrates' metabolomics and lipidomics technologies with Bruker's existing proteomics workflows.
• MolzymcoreTechnology or Integration · 1 January 2025Bruker integrated Molzym, acquired in late 2025, to strengthen its culture-independent pathogen diagnostics capabilities within the microbiology and infection diagnostics portfolio.
• AST Revolution, LLCcoreTechnology or Integration · 1 January 2025Bruker acquired AST Revolution, LLC, a developer of rapid antimicrobial susceptibility testing solutions, from Indaba Capital Management. The acquisition follows AST Revolution's launch after acquiring assets from Accelerate Diagnostics under Chapter 11 proceedings, expanding Bruker's infection diagnostics capabilities.
• Dynamic Biosensors GmbHcoreTechnology or Integration · 2 October 2024Bruker acquired Dynamic Biosensors GmbH, a Munich-based company specializing in biosensor technologies for molecular interaction analysis, enhancing Bruker's biophysical portfolio particularly high-throughput SPR instruments and single-cell Interaction Cytometry systems for drug discovery.
• NanoString Technologies Inc.coreTechnology or Integration · 1 May 2024Bruker acquired NanoString Technologies Inc. for approximately $392.6 million in cash in May 2024, expanding its spatial biology portfolio with gene expression profiling (GeoMx DSP), spatial transcriptomics (CosMx SMI), and spatial proteomics products.
• ELITechGroup SAScoreTechnology or Integration · 1 May 2024Bruker acquired ELITechGroup SAS for $930.9 million in May 2024 to expand its molecular diagnostic offerings for clinical laboratories and hospitals, gaining access to advanced sample-to-answer molecular platforms and infectious disease assay portfolios.
• Spectral Instruments ImagingcoreTechnology or Integration · 1 February 2024Bruker acquired Spectral Instruments Imaging in February 2024 to strengthen its preclinical imaging technology portfolio for life sciences and materials research applications.
• NioncoreTechnology or Integration · 1 January 2024Bruker acquired Nion in January 2024 to strengthen its electron microscopy capabilities and expand its product lineup in the scientific instrumentation sector.
• MIRO Analytical AGcoreStrategic or Co-development Partner · 4 October 2023Bruker announced a majority investment in MIRO Analytical AG, a company specializing in compact, high-precision QCL-based multi-gas analyzers. This partnership enhances Bruker's trace gas analysis portfolio for environmental and climate research applications.
• PhenomeXcoreTechnology or Integration · 17 August 2023Bruker completed the acquisition of PhenomeX for $108 million in cash in August 2023, enhancing its research tools for cellular and multiomic analysis to expand offerings in life science and diagnostics.
• Biognosys AGcoreStrategic or Co-development Partner · 3 January 2023Bruker acquired a majority stake in Biognosys, a provider of mass spectrometry-based proteomics solutions, forming a strategic partnership to leverage Biognosys' software and services with Bruker's timsTOF platform. Plans include opening a CRO laboratory in Massachusetts, US.
• Prolab InstrumentscoreTechnology or Integration · 19 January 2022Bruker acquired Prolab Instruments to enhance its multiomics solutions, focusing on advanced chromatography and autosampler technologies.

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific: The largest analytical instruments and life sciences tools company globally, with leading mass spectrometry (Orbitrap), chromatography, and diagnostics offerings. Directly comparable to Bruker's mass spec, NMR-adjacent, and clinical diagnostics businesses but with materially greater scale and breadth.
• Mettler-Toledo International: Precision laboratory instruments manufacturer spanning balances, pH meters, titrators, and lab automation. Overlaps with Bruker's industrial and quality-control segment offerings, including calibration/measurement instruments used in regulated labs.
• Revvity (formerly PerkinElmer): Provides analytical instruments, reagents, and software across life sciences, diagnostics, and applied markets. Comparable to Bruker in applied/industrial analytical instrumentation and life science consumables following the 2023 PerkinElmer divestiture.
• Sartorius AG: Bioprocessing and lab products company serving pharmaceutical and biopharma manufacturing. Comparable as a broader life-science tools incumbent with overlapping bioprocess analytics and bioanalytics offerings relevant to Bruker's biopharma customer base.

Direct peers

• Agilent Technologies: Major analytical instrument manufacturer with mass spectrometry (6546XT QTOF, 6495D triple quadrupole), LC, GC, FT-IR, and spectroscopy offerings overlapping Bruker's proteomics, metabolomics, and applied markets. Both companies target pharma, academic, and applied/industrial customers with similar go-to-market models.
• Waters Corporation: Direct competitor in mass spectrometry (Xevo G3 QTOF, Cyclic IMS) and LC, with strong positions in proteomics, biopharmaceutical characterization, and clinical applications. Closely comparable business model and customer base to Bruker's mass spec and life science franchises.
• Shimadzu Corporation: Japanese analytical instrument manufacturer competing across mass spectrometry (LCMS-8060), chromatography, X-ray (XRF/XRD), FT-IR, and spectroscopy - directly overlapping with most of Bruker's applied and life science instrument portfolio.
• JEOL Ltd. Japanese scientific instrument manufacturer with direct overlap in NMR spectroscopy and electron microscopy, both core Bruker franchises. Particularly comparable in advanced NMR (high-field systems) and high-resolution electron microscopy products.
• Bio-Rad Laboratories: Life science research and clinical diagnostics company with droplet digital PCR (QX200) and proteomics workflows that overlap with Bruker's molecular diagnostics and Biognosys proteomics offerings. Comparable customer base across pharma and academic life sciences.
• QIAGEN N.V. Molecular diagnostics and sample technologies company with PCR-based infectious disease testing (QIAstat-Dx) and digital PCR. Closely comparable to Bruker's ELITechGroup and MyGenius PRO molecular diagnostics business; its CEO also recently joined Bruker's board.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bruker
• YouTubeyoutube.com/user/brukertv
• Facebookfacebook.com/bruker.corp
• LinkedInlinkedin.com/company/bruker-corporation
• Instagraminstagram.com/brukercorp

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries14 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A52 records

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bruker